Host: Wenxin Xu, MD

Host: Sandy Srinivas, MD

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

Host: Peter Buch, MD, FACG, AGAF, FACP

Guest: William Grady, MD

While colorectal cancer is the second most common cause of cancer deaths, only a third of people between the ages of 45 and 75 are compliant with screening recommendations. However, cell-free DNA blood-based tests could become a new option for colorectal cancer screening. Dr. Peter Buch sits down with GI expert Dr. William Grady to discuss the efficacy of this new test and where it is in the FDA approval process.

Guest: Gilberto de Lima Lopes, Jr, MD, MBA, FASCO

Guest: Jyoti Patel, MD

The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstrated limited clinical benefit; however, newer selective MET TKIs, such as capmatinib and tepotinib, have improved efficacy and acceptable safety profiles. In this activity, our experts assess the role of the role of MET gene aberrations in NSCLC and optimal testing modalities, as well as the clinical evidence supporting the use of MET TKIs and the potential role of these therapies in other subsets of disease.

Host: Warner K. Huh, MD

Guest: Kimberly Levinson, MD, MPH

More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.

Guest: Sara A. Hurvitz, MD, FACP

HER2-Directed ADCs in Breast Cancer

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Emily Carroll, JD, MSW

The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.

Host: Jacob Sands, MD

Guest: Lori Pierce, MD, FASTRO, FASCO

With only 3% of practicing oncologists identifying as Black, and less than 5% identifying as Latinx, how can we ensure these patient populations are equally represented in medical practice? Dr. Jacob Sands meets with ASCO’s current President, Dr. Lori Pierce, a Professor of Radiation Oncology and Vice Provost for Academic and Faculty Affairs at the University of Michigan, to discuss ASCO’s plan to increase quality in cancer care and research.

Host: Jennifer Caudle, DO

Guest: Todd Askew

What’s being done to address the range of issues like the PPE shortage, lack of testing, and financial shortfalls encountered during the COVID-19 pandemic? Here to share his team’s advocacy efforts to help tackle these and other challenges is Todd Askew, the American Medical Association's Senior Vice President of Advocacy.

Guest: Mary Beth Pfeiffer

With cases being reported in every state and across 80 countries, Lyme disease has become one of the fastest growing vector-borne illnesses in the world. But have you ever wondered how this global health threat came to be? That’s what journalist Mary Beth Pfeiffer investigates in her book, Lyme: The First Epidemic of Climate Change, and with the ReachMD team.

Host: John Russell, MD

Guest: Meredith Wadman, BM, BCh, M.S.

Until the late 1960s, tens of thousands of American children suffered crippling birth defects if their mothers had been exposed to rubella, popularly known as German measles, while pregnant; there was no vaccine and little understanding of how the disease devastated fetuses.

In June 1962, a young biologist in Philadelphia, using human tissue samples sent from Sweden, produced a line of cells that allowed the creation of vaccines against rubella and other common childhood diseases. Two years later, in the midst of a massive German measles epidemic, the vaccine that would one day wipe out homegrown rubella was introduced. This vaccine has since protected more than 150 million people in the United States, and its development method has also led to other vaccines that have protected billions of people around the world from polio, rabies, chicken pox, measles, hepatitis A, shingles, and adenovirus.

Host Dr. John Russell chats with Meredith Wadman, author of The Vaccine Race: Science, Politics, and the Human Costs of Defeating Disease, about the story of both the science of this urgent race and the political and ethical controversies that nearly ended it prematurely.